Vivo Bio Tech Limited Stock

Equities

VIVOBIOT6

INE380K01017

Biotechnology & Medical Research

Delayed Bombay S.E. 04:00:07 2024-04-29 am EDT 5-day change 1st Jan Change
45.05 INR -0.02% Intraday chart for Vivo Bio Tech Limited +0.18% +36.10%
Sales 2022 514M 6.16M Sales 2023 522M 6.26M Capitalization 288M 3.45M
Net income 2022 22M 264K Net income 2023 26M 312K EV / Sales 2022 2.38 x
Net Debt 2022 657M 7.88M Net Debt 2023 610M 7.32M EV / Sales 2023 1.72 x
P/E ratio 2022
25.5 x
P/E ratio 2023
10.8 x
Employees 150
Yield 2022 *
-
Yield 2023
-
Free-Float 26.6%
More Fundamentals * Assessed data
Dynamic Chart
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vivo Bio Tech Limited Appoints Vaishnavi Kiran Ayinampudi as Company Secretary & Compliance Officer CI
Vivo Bio Tech Limited Announces the Resignation of Ms. Jyotika Aasat as Company Secretary & Compliance Officer of the Company with Effect from January 02, 2024 CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Vivo Bio Tech Limited Announces the Resignation of Hariharan Ravindran as Independent Director CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Vivo Bio Tech Limited Announces Resignation of Sunder Kanaparthy as Independent Director, Effective from April 1, 2023 CI
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vivo Bio Tech Limited announced a financing transaction CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Vivo Bio Tech Limited Announces Registered Office Address Changes CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Vivo Biotech Acquires Land in Telangana, India for $5 Million MT
More news
1 day-0.02%
1 week+0.18%
Current month+5.09%
1 month+0.85%
3 months+12.04%
6 months+33.17%
Current year+36.10%
More quotes
1 week
44.00
Extreme 44
46.90
1 month
43.00
Extreme 43
50.80
Current year
32.00
Extreme 32
56.00
1 year
21.05
Extreme 21.05
56.00
3 years
18.11
Extreme 18.11
115.10
5 years
17.50
Extreme 17.5
115.10
10 years
15.10
Extreme 15.1
115.10
More quotes
Managers TitleAgeSince
Director of Finance/CFO 44 21-11-02
Director/Board Member 80 -
Members of the board TitleAgeSince
Director of Finance/CFO 44 21-11-02
Chairman 41 20-06-29
Director/Board Member 45 16-07-28
More insiders
Date Price Change Volume
24-04-29 45.05 -0.02% 16 649
24-04-26 45.06 -0.24% 12,591
24-04-25 45.17 -0.88% 28,565
24-04-24 45.57 +1.86% 17,208
24-04-23 44.74 -0.51% 14,543

Delayed Quote Bombay S.E., April 29, 2024 at 04:00 am EDT

More quotes
Vivo Bio Tech Limited is a comprehensive pre-clinical clinical research organization (CRO) providing drug development and discovery services company. It operates in biotechnology segment. The Company offering drug development and discovery services to pharmaceutical and biotech companies. The Company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It provides both regulatory and non-regulatory IND enabling preclinical development services. The Company provides screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, it provides design and development of syngeneic / xenograft models for evaluation of anti-cancer agent. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.
More about the company
  1. Stock Market
  2. Equities
  3. VIVOBIOT6 Stock